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Background
Systemic lupus erythematosus (SLE) is a challenging dis-
ease to diagnose and manage. Treatment of lupus nephri-
tis in resistant cases is still a matter of debate.
Aim
To investigate the effectiveness of rituximab (Rx) in treat-
ment resistant cases of lupus nephritis.
Materials and methods
Five female patients with a median age of 14 years (range:
12–16 years) with class IV (3/5) and class II (2/5) lupus
nephritis were treated with rituximab, steroids and plas-
mapheresis. Rituximab was given with a dose of 375 mg/
m2/week for 4 weeks. Two patients had severe thrombo-
cytopenia, while one of them had developed macrophage
activating syndrome. All of them had renal failure with
high serum creatinine. ANA and anti ds DNA levels were
found to be high in 4 patients with low levels of comple-
man 3.
Results
Thrombocytopenia was completely resolved at the end of
4 weeks in both patients while only one patient had com-
plete remission of the SLE. Partial remission was observed
in two patients and 2 patients did not respond at all.
Conclusion
Rituximab could be effective in treatment of patients with
severe, treatment resistant lupus nephritis.
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